Differential Inhibition of Inducible T Cell Cytokine Secretion by Potent Iron Chelators

Abstract

Effector functions and proliferation of T helper (Th) cells are influenced by cytokines in the environment. Th1 cells respond to a synergistic effect of interleukin-12 (IL-12) and interleukin-18 (IL-18) to secrete interferon-gamma (IFN-γ). In contrast, Th2 cells respond to interleukin-4 (IL-4) to secrete IL-4, interleukin-13 (IL-13), interleukin-5 (IL-5), and interleukin-10 (IL-10). The authors were interested in identifying nonpeptide inhibitors of the Th1 response selective for the IL-12/IL-18-mediated secretion of IFN-γ while leaving the IL-4-mediated Th2 cytokine secretion relatively intact. The authors established a screening protocol using human peripheral blood mononuclear cells (PBMCs) and identified the hydrazino anthranilate compound 1 as a potent inhibitor of IL-12/IL-18-mediated IFN-γ secretion from CD3⁺ cells with an IC₅₀ around 200 nM. The inhibitor was specific because it had virtually no effect on IL-4-mediated IL-13 release from the same population of cells. Further work established that compound 1 was a potent intracellular iron chelator that inhibited both IL-12/IL-18- and IL-4-mediated T cell proliferation. Iron chelation affects multiple cellular pathways in T cells. Thus, the IL-12/IL-18-mediated proliferation and IFN-γ secretion are very sensitive to intracellular iron concentration. However, the IL-4-mediated IL-13 secretion does not correlate with proliferation and is partially resistant to potent iron chelation

Keywords

Th1 response iron chelators T helper cells cytokines

References

Murphy KM , Ouyang W , Farrar JD , Yang J , Ranganath S , Asnagli H , et al : Signaling and transcription in T helper development. Annu Rev Immunol 2000;18:451-494.

Murphy KM , Reiner SL : The lineage decisions of helper T cells. Nat Rev Immunol 2002;2:933-944.

O’Garra A , Arai N : The molecular basis of T helper 1 and T helper 2 cell differentiation. Trends Cell Biol 2000;10:542-550.

El-Mezzein RE , Matsumoto T , Nomiyama H , Miike T : Increased secretion of IL-18 in vitro by peripheral blood mononuclear cells of patients with bronchial asthma and atopic dermatitis. Clin Exp Immunol 2001;126:193-198.

Hoshino T , Wiltrout RH , Young HA : IL-18 is a potent coinducer of IL-13 in NK and T cells: a new potential role for IL-18 in modulating the immune response. J Immunol 1999;162:5070-5077.

Liew FY , McInnes IB : Role of interleukin 15 and interleukin 18 in inflammatory response. Ann Rheum Dis 2002;61:100-102.

Nakanishi K , Yoshimoto T , Tsutsui H , Okamura H : Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 2001;12:53-72.

Nakanishi K , Yoshimoto T , Tsutsui H , Okamura H : Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 2001;19:423-474.

Okamura H , Kashiwamura S , Tsutsui H , Yoshimoto T , Nakanishi K : Regulation of interferon-gamma production by IL-12 and IL-18. Curr Opin Immunol 1998;10:259-264.

10.

Ma X , Trinchieri G : Regulation of interleukin-12 production in antigen-presenting cells. Adv Immunol 2001;79:55-92.

11.

Kawakami K : Interleukin-18 and host defense against infectious pathogens. J Immunother 2002;25:S12-S19.

12.

Van den Berg WB : Lessons from animal models of arthritis. Curr Rheumatol Rep 2002;4:232-239.

13.

Rothe H , Kolb H : The APC1 concept of type I diabetes. Autoimmunity 1998;27:179-184.

14.

Lebel-Binay S , Berger A , Zinzindohoue F , Cugnenc P , Thiounn N , Fridman WH , et al : Interleukin-18: biological properties and clinical implications. Eur Cytokine Netw 2000;11:15-26.

15.

Asnagli H , Murphy KM : Stability and commitment in T helper cell development. Curr Opin Immunol 2001;13:242-247.

16.

Wills-Karp M , Chiaramonte M : Interleukin-13 in asthma. Curr Opin Pulm Med 2003;9:21-27.

17.

Foster PS , Martinez-Moczygemba M , Huston DP , Corry DB : Interleukins-4, -5, and -13: emerging therapeutic targets in allergic disease. Pharmacol Ther 2002;94:253-264.

18.

Coon ME , Diegel M , Leshinsky N , Klaus SJ : Selective pharmacologic inhibition of murine and human IL-12-dependent Th1 differentiation and IL-12 signaling. J Immunol 1999;163:6567-6574.

19.

Du C , Cooper JC , Klaus SJ , Sriram S : Amelioration of CR-EAE with lisofylline: effects on mRNA levels of IL-12 and IFN-gamma in the CNS. J Neuroimmunol 2000;110:13-19.

20.

Laurat E , Poirier B , Tupin E , Caligiuri G , Hansson GK , Bariety J , et al : Invivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 2001;104:197-202.

21.

Marcinkiewicz J , Grabowska A , Lauterbach R , Bobek M : Differential effects of pentoxifylline, a non-specific phosphodiesterase inhibitor, on the production of IL-10, IL-12 p40 and p35 subunits by murine peritoneal macrophages. Immunopharmacology 2000;49:335-343.

22.

Ohta Y , Yamane M , Sohda T , Makino H : TAK-603 selectively suppresses Th1-type cytokine production and inhibits the progression of adjuvant arthritis. Immunology 1997;92:75-83.

23.

Loseke S , Grage-Griebenow E , Wagner A , Gehlhar K , Bufe A : Differential expression of IFN-alpha subtypes in human PBMC: evaluation of novel real-time PCR assays. J Immunol Methods 2003;276:207-222.

24.

Richardson DR , Ponka P : Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease. J Lab Clin Med 1998;131:306-315.

25.

Trifillis AL , Regec AL , Trump BF : Isolation, culture and characterization of human renal tubular cells. J Urol 1985;133:324-329.

26.

Smythe JA , Fink PD , Logan GJ , Lees J , Rowe PB , Alexander IE : Human fibroblasts transduced with CD80 or CD86 efficiently trans-costimulate CD4+ and CD8+ T lymphocytes in HLA-restricted reactions: implications for immune augmentation cancer therapy and autoimmunity. J Immunol 1999;163:3239-3249.

27.

Venkataraman C , Leung S , Salvekar A , Mano H , Schindler U : Repression of IL-4-induced gene expression by IFN-gamma requires Stat1 activation. J Immunol 1999;162:4053-4061.

28.

Ishiyama M , Tominaga H , Shiga M , Sasamoto K , Ohkura Y , Ueno K : A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol Pharm Bull 1996;19:1518-1520.

29.

Gao J , Richardson DR : The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: the mechanisms involved in inhibiting cell-cycle progression. Blood 2001;98:842-850.

30.

Darnell G , Richardson DR : The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation. Blood 1999;94:781-792.

31.

Thorson JA , Smith KM , Gomez F , Naumann PW , Kemp JD : Role of iron in T cell activation: TH1 clones differ from TH2 clones in their sensitivity to inhibition of DNA synthesis caused by IgG Mabs against the transferrin receptor and the iron chelator deferoxamine. Cell Immunol 1991;134:126-137.

32.

Grant SM , Wiesinger JA , Beard JL , Cantorna MT : Iron-deficient mice fail to develop autoimmune encephalomyelitis. J Nutr 2003;133:2635-2638.

33.

Weiss G : Iron and immunity: a double-edged sword. Eur J Clin Invest 2002;32:70-78.